Telomir Pharmaceuticals (TELO) Stock Price, News & Analysis

Company Overview

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

Key Stats

• Today's Range: $2.61 to $3.08
• 50-Day Range: $2.74 to $5.03
• 52-Week Range: $2.61 to $9.39
• Volume: 178,838 shs
• Average Volume: 123,191 shs
• Market Capitalization: $87.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Strong Buy

Telomir Pharmaceuticals Stock Analysis - MarketRank™

Telomir Pharmaceuticals scored higher than 28% of companies evaluated by MarketBeat, and ranked 768th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Telomir Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Telomir Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Telomir Pharmaceuticals are expected to grow in the coming year, from ($0.40) to ($0.36) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Telomir Pharmaceuticals is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Telomir Pharmaceuticals is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Telomir Pharmaceuticals has a P/B Ratio of 146.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.30% of the float of Telomir Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Telomir Pharmaceuticals has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Telomir Pharmaceuticals has recently increased by 4.28%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Telomir Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Telomir Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.30% of the float of Telomir Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Telomir Pharmaceuticals has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Telomir Pharmaceuticals has recently increased by 4.28%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for TELO on MarketBeat in the last 30 days.

MarketBeat Follows

5 people have added Telomir Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Telomir Pharmaceuticals insiders have not sold or bought any company stock.

TELO Stock Analysis - Frequently Asked Questions

How have TELO shares performed this year?

Telomir Pharmaceuticals' stock was trading at $4.12 at the beginning of the year. Since then, TELO shares have decreased by 28.9% and is now trading at $2.93.
View the best growth stocks for 2025 here.

How were Telomir Pharmaceuticals' earnings last quarter?

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) released its quarterly earnings results on Tuesday, February, 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.05.

When did Telomir Pharmaceuticals IPO?

Telomir Pharmaceuticals (TELO) raised $7 million in an initial public offering on Friday, February 9th 2024. The company issued 1,000,000 shares at $7.00 per share. Kingswood Investments served as the underwriter for the IPO.

How do I buy shares of Telomir Pharmaceuticals?

Shares of TELO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 2/04/2025
• Today: 4/04/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TELO
• Previous Symbol: NASDAQ:TELO
• CIK: 1971532
• Web: telomirpharma.com
• Phone: (737)-289-0835
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $15.00
• High Stock Price Target: $15.00
• Low Stock Price Target: $15.00
• Potential Upside/Downside: +411.9%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-16,530,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,170.58%
• Return on Assets: -832.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.94
• Quick Ratio: 1.94

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.02 per share
• Price / Book: 146.50

Miscellaneous

• Outstanding Shares: 29,763,000
• Free Float: N/A
• Market Cap: $87.21 million
• Optionable: N/A
• Beta: 0.01